Hormonal IUD (Mirena/Kyleena) and Acetaminophen: What Women Need to Know

The Short Answer on This Drug Combination

There is no clinically significant pharmacokinetic interaction between levonorgestrel-releasing IUDs (Mirena 52 mg, Kyleena 19.5 mg, Liletta 52 mg) and acetaminophen at ordinary analgesic doses. The FDA prescribing information for Mirena does not list acetaminophen as a contraindicated or interacting drug. The FDA monograph for acetaminophen similarly lists no contraindication with hormonal contraceptives.

Both drugs are processed by the liver, and women who take acetaminophen every day, at high doses, or alongside other hepatotoxic agents should understand where the biochemical overlap sits.

What Makes This Question Worth Answering Carefully

Millions of women who have a hormonal IUD will reach for acetaminophen at some point, whether for cramps in the first months after insertion, a headache, or a chronic pain condition. Pain management after IUD insertion is a real, documented clinical need, and the question of which analgesic is safest deserves a direct answer rather than a vague "ask your doctor."

How Levonorgestrel IUDs Work in the Body

Levonorgestrel-releasing IUDs deliver hormone locally to the uterine cavity. Systemic absorption is intentionally low. Mirena releases approximately 20 micrograms per day initially, declining to about 10 mcg/day after 5 years. Kyleena releases approximately 17.5 mcg/day, dropping to 7.4 mcg/day by year 5.

Systemic Hormone Levels Are Low

Because systemic levonorgestrel concentrations from an IUD are far lower than from oral pills or implants, the hormonal drug-interaction profile is narrower. Oral levonorgestrel pills can be meaningfully affected by CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) because first-pass hepatic metabolism governs their bioavailability. With an IUD, local uterine concentrations drive contraceptive action, so even modest changes in systemic metabolism matter much less to efficacy.

How Levonorgestrel Is Metabolized

Once levonorgestrel reaches systemic circulation, it undergoes hepatic metabolism primarily via CYP3A4 and phase II glucuronidation and sulfation. The resulting metabolites are excreted renally. Serum binding to sex hormone-binding globulin (SHBG) influences free-fraction availability, and anything that alters SHBG or CYP3A4 activity can in theory change circulating levonorgestrel levels, though the clinical relevance is minimal at IUD doses.

How Acetaminophen Is Metabolized

Acetaminophen (paracetamol, Tylenol) is cleared by three competing hepatic pathways. At therapeutic doses, roughly 90% is conjugated by glucuronidation (UGT enzymes) and sulfation, producing non-toxic metabolites. The remaining approximately 5-10% passes through CYP2E1 (and to a lesser extent CYP3A4) to generate the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). Glutathione neutralizes NAPQI under normal circumstances. Overdose or chronic high-dose use depletes glutathione, allowing NAPQI to accumulate and cause hepatocellular necrosis.

Where Levonorgestrel and Acetaminophen Overlap

The biochemical meeting point is phase II glucuronidation. Both acetaminophen and levonorgestrel (and many steroid hormones) rely on UDP-glucuronosyltransferase (UGT) enzymes for a portion of their clearance. In theory, high-flux acetaminophen metabolism could compete for UGT capacity, slightly altering levonorgestrel conjugation. In practice, no published clinical pharmacokinetic study has demonstrated a meaningful change in levonorgestrel plasma levels from concurrent acetaminophen use. The enzyme system has enough redundancy and reserve capacity that standard analgesic doses do not saturate UGT to a clinically relevant degree.

CYP3A4 Overlap Is Minimal

Acetaminophen uses CYP3A4 as a minor pathway, not a primary one. At therapeutic doses, CYP3A4-mediated acetaminophen metabolism is small enough that it does not meaningfully compete with levonorgestrel clearance.

Does Acetaminophen Reduce Hormonal IUD Effectiveness?

No. The contraceptive mechanism of a levonorgestrel IUD depends primarily on local intrauterine effects: thickening cervical mucus to block sperm penetration, thinning the endometrial lining, and impairing sperm motility. These effects are driven by the sustained local concentration in the uterus, not by the systemic hormone level. Even if acetaminophen modestly altered systemic levonorgestrel pharmacokinetics (and there is no evidence it does), the local intrauterine reservoir would remain unaffected.

ACOG Practice Bulletin No. 186 on long-acting reversible contraception does not list acetaminophen as a drug that compromises IUD efficacy, and neither does the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 5th edition.

The Hepatic Toxicity Overlap: Who Needs to Pay Attention

Both acetaminophen and levonorgestrel (like all steroids) are processed by the liver. This is not a reason to avoid the combination, but it is a reason to maintain sensible acetaminophen habits. Acetaminophen hepatotoxicity is the leading cause of acute liver failure in the United States, responsible for approximately 46% of all acute liver failure cases. Nearly all cases involve overdose, chronic alcohol use, or polypharmacy with other hepatotoxins.

Women-Specific Hepatic Risk Factors

Women with certain conditions common in the hormonal IUD user population should apply extra caution:

• PCOS with metabolic dysfunction-associated steatotic liver disease (MASLD): PCOS affects an estimated 6-13% of reproductive-age women and carries elevated rates of liver steatosis. In this group, the liver's detoxification reserve may already be reduced.
• Autoimmune hepatitis and primary biliary cholangitis: Both disproportionately affect women and reduce hepatic clearance capacity.
• Chronic daily analgesic use: Women managing endometriosis-related or fibromyalgia-related chronic pain may take acetaminophen daily. The safe upper limit in adults with normal liver function is 4,000 mg per day, though many hepatologists recommend no more than 3,000 mg/day as a practical ceiling.
• Regular alcohol use: Alcohol induces CYP2E1, the enzyme that generates NAPQI. Even moderate drinking (more than one drink daily) combined with regular acetaminophen use increases NAPQI burden.

What Monitoring Looks Like in Practice

For most women with a hormonal IUD who occasionally take acetaminophen, no specific monitoring is needed beyond standard clinical care. A practical framework for the subset who use acetaminophen more than 10 days per month:

1. Keep a current list of all medications and supplements, including those containing hidden acetaminophen (many combination cold, sleep, and migraine products contain 325-500 mg per tablet).
2. If acetaminophen is used daily for more than 2 weeks continuously, ask your clinician whether a baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) is warranted.
3. If you have PCOS, a prior history of elevated liver enzymes, or active hepatic disease, annual liver function testing is reasonable even without IUD-specific concern.
4. Alcohol and acetaminophen should not be combined regularly. The FDA label for acetaminophen carries a boxed warning that adults who consume three or more alcoholic drinks per day should consult a clinician before use.

Acetaminophen for IUD Insertion Pain

The question of acetaminophen and the hormonal IUD is most practically relevant at insertion. IUD insertion causes uterine cramping that ranges from mild to severe. The Cochrane review on interventions for pain with IUD insertion (2015) found that evidence for most analgesic interventions was limited, but acetaminophen is consistently included in clinical protocols as part of a multimodal pre-procedure approach.

A randomized trial by Bednarek et al. (2013) published in Obstetrics and Gynecology found that 1,000 mg ibuprofen did not significantly reduce insertion pain versus placebo, which generated interest in whether acetaminophen alone or in combination is more effective. Given that NSAIDs block prostaglandins (the main mediator of insertion-related cramping), the current evidence base more robustly supports ibuprofen 600-800 mg pre-procedure if you have no contraindication to NSAIDs. Acetaminophen is a reasonable alternative if NSAIDs are contraindicated, for example in women with peptic ulcer disease, renal impairment, or third-trimester pregnancy (see section below).

Practical Dosing for Insertion Day

If your clinician recommends acetaminophen before IUD insertion:

• Take 1,000 mg (two regular-strength 500 mg tablets) approximately 1 hour before the procedure.
• Do not exceed the single-dose ceiling of 1,000 mg.
• Continue with 500-1,000 mg every 6-8 hours as needed for the first 24-48 hours post-insertion, staying below 4,000 mg in 24 hours.
• Heating pads applied to the lower abdomen can provide meaningful additive relief without any pharmacokinetic concern.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy Status and the IUD

A functioning hormonal IUD has a failure rate of approximately 0.1-0.8% per year. If pregnancy occurs with an IUD in place, the device should be removed as soon as possible because of the risk of septic abortion and preterm delivery. Should you become pregnant with an IUD in place and acetaminophen becomes relevant (for example, for pain associated with the situation), the following applies.

Acetaminophen in Pregnancy: What the Evidence Actually Says

Acetaminophen has long been considered the safest OTC analgesic in pregnancy, but this position has been revisited. The FDA issued a communication in 2023 updating its guidance noting that NSAIDs are contraindicated after 20 weeks of gestation because of fetal renal effects and premature ductus arteriosus closure, making acetaminophen the default analgesic in the second half of pregnancy.

However, a 2021 consensus statement in Nature Reviews Endocrinology, signed by 91 scientists and clinicians, raised concern that prolonged prenatal acetaminophen exposure may be associated with altered fetal reproductive and neurodevelopmental outcomes. The operative word is prolonged. Occasional, short-course use at the lowest effective dose is not contraindicated. ACOG's 2023 guidance states that acetaminophen remains appropriate for pain and fever in pregnancy when used at the lowest effective dose for the shortest time needed.

The bottom line: if you are pregnant (whether after IUD failure or for any other reason), use acetaminophen only as needed, at minimum effective doses, and for the shortest duration. Avoid chronic daily use throughout pregnancy.

Acetaminophen During Lactation

Acetaminophen is compatible with breastfeeding. Transfer into breast milk is low, and infant exposure is estimated at roughly 1-2% of the maternal dose. LactMed, the NIH's peer-reviewed lactation database, lists acetaminophen as a preferred analgesic during breastfeeding. No dose adjustment of the maternal regimen is required.

Levonorgestrel IUD During Lactation

Mirena and Kyleena are category 2 per WHO MEC (generally safe) for use during lactation. The low systemic levonorgestrel levels from an IUD are not expected to adversely affect milk supply or infant development when the device is placed 4 weeks or more postpartum. ACOG endorses IUD placement as early as immediately postpartum (within 10 minutes of placental delivery), though expulsion rates are higher with immediate placement.

Contraception Note

The levonorgestrel IUD itself is the contraceptive in this scenario. Acetaminophen has no interaction with its contraceptive action. No additional contraceptive precaution is needed when using acetaminophen alongside your IUD.

Who This Is Right For and Who Should Be Cautious

Women Who Can Use Acetaminophen Freely With Their Hormonal IUD

• Reproductive-age women with a normally functioning liver and no chronic hepatic disease
• Perimenopausal women using Mirena for heavy menstrual bleeding (HMB) or endometrial protection during hormone therapy
• Women with NSAID contraindications (peptic ulcer, aspirin-exacerbated respiratory disease, renal insufficiency) who need an analgesic alternative
• Breastfeeding women who have a postpartum Mirena or Liletta

Women Who Should Use Acetaminophen With Greater Awareness

• Women with PCOS and confirmed hepatic steatosis or elevated baseline liver enzymes
• Women with autoimmune liver conditions
• Women who drink alcohol regularly (more than 7 drinks per week)
• Women on other hepatotoxic medications: isoniazid, methotrexate, statins at high doses, some antiepileptics
• Women managing endometriosis or fibromyalgia with near-daily acetaminophen

For this second group, the interaction is not a reason to avoid acetaminophen, but it is a reason to use the minimum effective dose, avoid combining with alcohol, and keep your clinician informed.

Other Hormonal IUD Drug Interactions Worth Knowing

While acetaminophen does not interact meaningfully with levonorgestrel IUDs, other drugs do warrant attention in women who have one.

Strong CYP3A4 inducers can lower systemic levonorgestrel levels. Though this matters more for oral progestins than for IUDs, clinicians sometimes flag the following: rifampin, certain antiseizure medications (phenytoin, carbamazepine, phenobarbital), and the herbal supplement St. John's Wort. For an IUD user, the primary concern with these drugs is the theoretical (and likely small) reduction in systemic progestin, not a meaningful loss of contraceptive protection given the predominantly local mechanism. The WHO MEC does not restrict IUD use in women taking enzyme inducers.

NSAIDs deserve a specific note. There is no evidence that ibuprofen, naproxen, or other NSAIDs reduce levonorgestrel IUD efficacy. The theoretical concern that prostaglandin inhibition might alter cervical mucus or implantation in ways that undermine the IUD has not been borne out in clinical data. You can take NSAIDs for cramps or other pain without worrying about your IUD stopping work.

Sex-Specific Pharmacokinetic Differences in Acetaminophen Metabolism

Women metabolize acetaminophen somewhat differently than men. A study in the Journal of Clinical Pharmacology found that women have higher acetaminophen glucuronidation rates than men, resulting in faster clearance of the glucuronide conjugate. This means women, on average, clear acetaminophen slightly faster and may have a modestly lower peak plasma concentration after the same weight-adjusted dose.

Practically, this does not change standard dosing recommendations. But it does mean that the frequently cited male-default pharmacokinetic data may slightly overestimate acetaminophen exposure in women at identical doses. The evidence gap here is real: most early acetaminophen PK studies enrolled primarily male subjects, and sex-stratified data in large populations are limited.

Hormonal status also influences glucuronidation. Estrogen and progesterone fluctuate across the menstrual cycle and at menopause, and both can modulate UGT enzyme expression. The clinical magnitude of this effect on acetaminophen clearance is small and not well-characterized in women specifically using hormonal IUDs. This is an area where we are extrapolating from general pharmacological principles rather than drawing on direct trial data in IUD users.

A Note on Evidence Quality

The absence of major interaction data between levonorgestrel IUDs and acetaminophen is itself meaningful. No major pharmacovigilance database (FDA Adverse Event Reporting System, WHO VigiBase) has flagged a safety signal for this combination. No DDI (drug-drug interaction) database including Lexicomp, Micromedex, or Clinical Pharmacology rates this combination above "minimal" risk. The interaction checker maintained by the National Institutes of Health DailyMed returns no interaction for levonorgestrel IUD and acetaminophen.

Women have historically been underrepresented in pharmacokinetic and drug-interaction trials, including those involving hormonal contraceptives. The data on this specific combination in women across different life stages, including perimenopausal women and those with PCOS-related hepatic changes, is thin. Extrapolation from general glucuronidation competition studies and from broader acetaminophen PK work in women is reasonable, but it is extrapolation, not direct evidence.